Thus, E177R expression elicited in B- and T-cell lymphoma models a similar therapeutic response as in AML, indicating that even partial restoration of p53 function is able to induce regression in different hematopoietic cancers. The gene discussed is TP53; the disease is hematopoietic and lymphoid cell neoplasm.